Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A PROSPECTIVE LOW-INTERVENTIONAL PHASE 4 SINGLE ARM STUDY OF OCULAR ASSESSMENTS IN PATIENTS TREATED WITH TIVDAK® IN RECURRENT OR METASTATIC CERVICAL CANCER

NCT06952660 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT06952660
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06952660 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A PROSPECTIVE LOW-INTERVENTIONAL PHASE 4 SINGLE ARM STUDY OF OCULAR ASSESSMENTS IN PATIENTS TREATED WITH TIVDAK® IN RECURRENT OR METASTATIC CERVICAL CANCER
Lead sponsor
Pfizer
Phase
Phase 4
Overall status
Recruiting
Start date
May 7, 2025
Completion date
December 13, 2028
Enrollment
100 (estimated)
Sites
132

Conditions

As the registry lists them; a condition with its own page is linked.

cervical cancer